



GAMMA WEST
CANCER SERVICES

Brachytherapy

Administrative Offices

Gamma West Cancer Services
24 South 1100 East, Suite 306
Salt Lake City, Utah 84102-1507
Phone: 801-359-8956

Salt Lake Regional Medical Center

Gamma West Cancer Services
1050 East South Temple
Salt Lake City, Utah 84102
Phone: 801-350-8400

Ogden Regional Medical Center

Gamma West Cancer Services
425 East 5350 South Suite 180
Ogden, Utah 84405
Phone: 801-475-4571

Timpanogos Regional Hospital

Gamma West Cancer Services
674 West 800 North Suite B-10
Orem, Utah 84057
Phone: 801-852-0210

St. George, Utah

Gamma West Cancer Services
1490 E. Foremaster Drive, Building C
St. George, UT 84790
Phone: 435-627-5327

gammawest.com

May 11, 2010

Dear Physician,

For the past 12 years, GammaWest Cancer Services (GammaWest) has been providing curative brachytherapy (“brachy” from the Greek word for “close to”) treatment for prostate and breast cancer. From our early inception, we have had the goal of providing excellent, careful, cost-effective treatments utilizing radiation as an alternative to surgery and other forms of therapy.

Over this past decade, GammaWest has been a regional referral center for the Intermountain West, presently with 7 clinics throughout the State of Utah including St. George, Orem, SLC (2), Layton and Ogden (2). Owing to superb outcomes, professional meeting presentations and publications, we have built a national and international reputation, and our patients now come from all over the world for curative treatment of their cancer.

The purpose of this letter is to share with you our exciting results with intermediate-risk prostate cancer patients over the past 8 years. We presented this data at the Western Section of the American Urological Association meeting held in October, 2009 and were honored to further present an updated version of our excellent results earlier this month to the American Brachytherapy Society annual meeting in Atlanta, GA.

➤ Highlights of our recent presentation and upcoming peer-reviewed publication include:

- From 2002 to 2009 we treated 1,260 patients with High Dose Rate brachytherapy at GammaWest Cancer Services, as the sole treatment for their prostate cancer.
- Our analysis included 284 patients with intermediate-risk prostate cancer (T2b/T2c, Gleason score 7, and/or PSA 10-20) and with follow-up exceeding 1 year.
- The 5 year cause-specific survival was 100%, overall survival 99.1%, and distant-metastasis-free survival was 98.8%.
- Biochemical recurrence has developed in only 7 patients for a 5-year biochemical disease-free survival (bDFS) of 94.4%.
- Although patients do occasionally develop modest increases in their International Prostate Symptom Scores (IPSS) at 3 and 6 months after treatment, these changes are small, not statistically significant, and not sustained. Our intermediate-risk patients experienced no significant change in their IPSS over time.
- Erectile function is preserved in 75% of patients who are potent before treatment.
- Although we have seen rare urethral strictures in prior patients, we have now developed a careful practice of excluding the membranous urethra from high dose irradiation, and no patient in the nearly 300 member intermediate-risk group has had a stricture.
- High Dose Rate brachytherapy provides excellent long-term biochemical control with a very favorable toxicity profile. Patients can typically return to work or normal activities immediately after the completion of treatment.

Please see the enclosed copy of our abstract presented at the Western Section of the American Urological Association meeting held last year. An updated abstract has been published in the most recent edition of the journal *Brachytherapy*. For further information about High-Dose Rate Brachytherapy as a curative treatment for prostate cancer, please visit our website (www.gammawest.com) where you can also obtain a copy of the complete abstract.

We hope that when prostate cancer presents itself in your clinical practice, you will feel comfortable in educating your patients about the benefits of treating prostate cancer with High Dose Rate brachytherapy.

Warm Regards,

Dave Vincent
Chief Executive Officer
Gamma West Cancer Services